Natera's revenue growth is accelerating, driven by oncology volumes exceeding one million tests for a second consecutive quarter in 2026Q2, with revenue up 37.7% YoY to $752.8M.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 37.7% YoY in 2026Q2, reaching $752.8M, while gross margin improved to 64.5% from 56.7% in 2024Q1, but operating margin remained negative at -10.1% due to rising R&D and SG&A costs.
Natera issued 2026 revenue guidance of US$2.62 billion to US$2.70 billion, indicating strong growth expectations.
New clinical data on Signatera test presented at ASCO Genitourinary Cancers Symposium highlights its potential in muscle-invasive bladder cancer.
NTRA's oncology franchise, particularly Signatera MRD testing, is a key growth driver supported by increasing testing volumes.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.42-49.3% vs -$0.28 | $794M+12.2% vs $708M |
Q3 2026 Aug 6, 2026 | -$0.47+4.8% vs -$0.49 | $753M+13.8% vs $661M |
Q2 2026 May 7, 2026 | -$0.56-3.3% vs -$0.54 | $697M+12.9% vs $617M |
Q1 2026 Feb 26, 2026 | $0.35+168.3% vs -$0.51 | $666M+10.2% vs $604M |
Natera, Inc. (NASDAQ: NTRA - Get Free Report) insider Solomon Moshkevich sold 3,419 shares of the firm's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $409.77, for a total transaction of $1,401,003.63. Following the transaction, the insider directly owned 101,323 shares in the company, valued at approximately
Natera, Inc. (NASDAQ: NTRA - Get Free Report) CEO Steven Chapman sold 3,801 shares of Natera stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $411.80, for a total transaction of $1,565,251.80. Following the completion of the transaction, the chief executive officer directly owned 87,431 shares of the
Natera, Inc. ( NTRA ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of Clinical Diagnostics Alexey Aleshin - GM of Oncology and Early Cancer Detection & Chief Medical Officer Conference Call Participants Daniel Brennan - TD Cowen, Research Division Puneet Souda - Leerink Partners LLC, Research Division Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to Natera's Second (sic) [ Third ] Quarter 2026 Earnings Conference Call.
Natera Inc. (NASDAQ:NTRA) shares are plunging Friday after reporting mixed third-quarter results, with revenue and guidance beating estimates while the loss per share came in wider than analysts expected. Here's what you should know.
Benchmark NTRA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Natera, Inc. (NTRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $310.67 | $44.49B | -271.73 | 35.9% | -5.66% | -9.18% | — | |
| $213.13 | $32.25B | 36.67 | -0.78% | 19.72% | 31.45% | — | |
| $1.96 | $185.32M | 5.27 | 161.14% | 47.55% | 42.57% | — | |
| $262.91 | $4.09B | 21.39 | 8.79% | 4.48% | 26.32% | — | |
| $2.26 | $701.96M | -5.36 | 3.89% | -81.31% | -2618.51% | — | |
| $4.65 | $839.87M | -4.39 | 55.28% | -4613.11% | -188.27% | — |
Natera, Inc. (NTRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Natera, Inc. (NTRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 6, 2026·SEC
Jun 16, 2026·SEC
Feb 27, 2026·SEC
Get notified when NTRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Natera, Inc. (NTRA) stock FAQ — growth, dividends, profitability & financials explained
Natera, Inc. (NTRA) reported $2.91B in revenue over the trailing twelve months. Revenue was $2.31B in fiscal year 2025. That is 16083% more than the $14.3M of fiscal year 2012.
Natera, Inc. (NTRA) grew revenue by 37.4% over the trailing twelve months, compared with the twelve months before.
No. Natera, Inc. (NTRA) reported a net loss of $164.7M over the trailing twelve months.
Natera, Inc. (NTRA) had a return on equity (ROE) of -9.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
Natera, Inc. (NTRA) generated $52.5M in free cash flow over the trailing twelve months.
